🎉 Happy New Year! 🎉 As we look back on 2024, we’re filled with gratitude for an incredible year at Palleon. Some highlights include Li Peng being named to the PharmaVoice 100, our exciting collaboration with Henlius, and celebrating many meaningful moments as a team. We are grateful for these accomplishments and for the continued dedication of our team, partners, and supporters. Together, we’re leading the way in glyco-immunology, targeting cell surface sugars to transform the treatment of autoimmunity and cancer. Here’s to 2025 and all that lies ahead! 🌟 #HappyNewYear
Palleon Pharmaceuticals
Biotechnology Research
Waltham, Massachusetts 6,441 followers
Clinical-stage biotech company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases
About us
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
- Website
-
http://www.palleonpharma.com
External link for Palleon Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Biotechnology, Immuno-Oncology, Clinical Development, and Glyco-Immune Checkpoint Inhibitors
Locations
-
Primary
266 Second Ave
Waltham, Massachusetts 02451, US
Employees at Palleon Pharmaceuticals
Updates
-
🚀 Exciting news! Palleon and Henlius will collaborate to evaluate glycan editing to enhance B cell depletion in #LupusNephritis. This marks the first clinical application of glyco-immunology in autoimmune diseases. Read more in our latest press release: https://bit.ly/3ZQCM3w #glycotime #lupusawareness
-
🎄 Team Palleon wishes you a warm and wonderful holiday season! As we wrap up the year, we hope everyone takes some time to rest, recharge, and enjoy the holidays. Yesterday, we celebrated together with a festive Yankee Swap and an Ugly Sweater Contest. Congrats to Mandy Evers for wearing the best ugly sweater! Spending quality time with our team was a perfect way to end the year. Wishing you a joyful and restful holiday! #HappyHolidays #TeamPalleon
-
🎉 Congratulations to Michael Kemp, M.S./PhD winner of a Palleon Innovation Award! Michael’s exceptional work has greatly strengthened our autoimmunity programs, driving innovation and impact. Thank you, Michael, for your dedication, expertise, and the many contributions you bring to our team! #PalleonPeople #glycotime
-
🎉 Congratulations to Wayne Gatlin, Lizhi Cao, Michael Kemp, M.S./PhD, Hui Xu, Hrishikesh Mehta, Maryann Timins, and Mark Yang for winning a Palleon Innovation and Collaboration Award! Your hard work and collaboration in advancing innovative EAGLE platform designs is truly inspiring. This award is a testament to your dedication and teamwork. We’re proud to celebrate your achievements and the positive impact you make on our team! #PalleonPeople #glycotime
-
Happy Nobel Prize Day! Today, we celebrate the incredible achievements of Nobel Prize winners who have improved our health and well-being through their contributions to the fields of physics, chemistry, medicine, literature, economics, and diplomacy. Their accomplishments underscore the power of curiosity, dedication, and innovation to make a lasting impact on our world. 🌍💡 #NobelPrizeDay
-
Exciting news from #ASH24! Palleon contributed to new research showing promising ways to enhance treatment for #MultipleMyeloma. Led by Dr. Michael O'Dwyer and Dr. Aideen E Ryan, this work reflects our commitment to advancing new options for patients. 🔗 https://bit.ly/4fUFw6L
-
🌍 Happy International Volunteer Day! Today, we’re celebrating Sabrina Nicholson who has served on the New England Village, Inc. Board since 2006, championing the right for people with disabilities to make their own choices. New England Village supports over 150 individuals with intellectual and developmental disabilities, including autism, Down syndrome, and sensory disabilities. Every program is tailored to meet each person's unique needs, fostering independence and inclusion. Thank you, Sabrina, for your dedication and impact! 💙 #PalleonPeople #InternationalVolunteerDay
-
🚀 Tomorrow marks the start of the Advances and New Horizons in Glycobiology conference in London, UK! This event will bring together leading experts to discuss breakthrough topics in glycobiology, from glycan structure and function to cutting-edge chemical biology methods, analytics, and impactful applications in biotechnology and medicine. Check out the full schedule here: https://bit.ly/3YMLPBP #glycotime